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Extracellular vesicleExtracellular vesicles (EVs) contain microRNAs (miRNAs). However, the exact molecular mecha-
nisms of the recruitment of miRNAs in EVs are not well characterized. Based on proteomic analysis,
we identified that silencing of Annexin A2 (ANXA2) significantly decreased the amount of miRNAs in
EVs. In addition, microarray analysis revealed that ANXA2 regulated the loading of miRNAs into EVs
in a sequence independent manner. Lastly, immunoprecipitation analysis confirmed that ANXA2
could bind miRNAs in EVs in the presence of Ca2+. These observations demonstrate that ANXA2 plays
an important role in the packaging process of miRNAs into EVs.
 2015 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical
Societies. This is an open access article under the CC BY license (http://creativecommons.org/licenses/
by/4.0/).1. Introduction
Small non-coding RNA microRNAs (miRNAs) regulate gene
expression at the post-transcriptional level by binding sequence-
specific sites within the 30 untranslated region of target mRNAs
[1]. In addition, miRNAs can fine-tune various biological processes,
including development, organogenesis, metabolism, and home-
ostasis [2]. miRNAs have been found in human body fluids despite
the abundant presence of ribonucleases (RNases) [3]. This finding
has led to the proposal of a scenario in which miRNAs could be
packaged in certain RNase-resistant containers when they are
secreted out of cells. Indeed, it has been reported that miRNAs
are present in extracellular vesicles (EVs), as has been described
for various body fluids [4]. Moreover, recent evidence suggests thatEV miRNAs in body fluids can exhibit disease-specific signatures
and can be used as biomarkers [5]. Another major interest is the
notion that EVs allow the transfer of miRNAs between cells.
Remarkably, such transferred miRNAs can be functional once they
have been incorporated into the recipient cells [6–8].
The findings have raised the idea that EVs could be used as car-
riers for effective drug delivery strategies. Indeed, Ohno et al. gen-
erated modified EVs derived from HEK293 cells expressing EGF or
GE11 peptide, another ligand for the EGF receptor, on their sur-
faces. These modified EVs successfully delivered let-7a miRNA to
EGFR-expressing xenografted breast cancer tissue in immunodefi-
cient mice [9]. However, the precise molecular mechanisms
responsible for miRNA loading into EVs remain unclear, preventing
EVs from being considered for further development and clinical
applications of these vesicles.
Considering that miRNAs generally exist as complexes with
proteins, it is conceivable that certain proteins form miRNA–pro-
tein complexes and recruit bound miRNAs into EVs. Intriguingly,
however, multiple studies reported that the Argonaute2 protein,
which binds to RNAs including miRNAs and plays a central role
in RNAi, does not bind to miRNAs in EVs [10,11]. Thus, other
RNA-binding proteins appear to contribute to miRNA–protein
complex formation and the subsequent loading of miRNAs into
EVs. Of note, it is likely that RNA-binding proteins typically bind
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recognize the secondary structure of miRNAs, but not their specific
sequence of them [12].
Based on this background, in this study, we explored proteins
that commonly recruit miRNAs into EVs. Following our proteomic
analysis, we identified 8 candidate proteins and focused on the
calcium-dependent binding protein Annexin A2 (ANXA2) as the
most promising candidate for further analyses. Indeed, a miRNA
microarray analysis showed that both control and ANXA2 knock-
down cell-derived EVs contain similar miRNA profiles, despite a
decrease in the quantity of loaded miRNAs in the ANXA2-
knockdown EVs, suggesting ANXA2-mediated non-selective load-
ing of miRNAs into EVs. Knockdown and overexpression of ANXA2
decreased and increased, respectively, the total amounts of
miRNAs in EVs without changing the intracellular levels of the
miRNAs. Taken together, we propose that the loading process of
miRNAs into EVs is mediated by ANXA2 in a sequence independent
manner.2. Materials and methods
2.1. Reagents
Mousemonoclonal anti-CD9 (sc-59140), mousemonoclonal anti-
human CD81 (sc-23962) and goat polyclonal anti-Alix (sc-49268)
were purchased from Santa Cruz Biotechnology. Mouse monoclonal
anti-ANXA2 (610068) was obtained from BD Biosciences. The
recombinant human ANXA2 protein was purchased from ProSpec.
Anti-FLAGM2magnetic beads were obtained from Sigma–Aldrich.
2.2. Plasmids
The pcDNA3 (V790-20) was purchased from Addgene. For the
immunoprecipitation assay, a FLAG-tagged ANXA2 overexpression
vector was constructed by introducing the following sequence at
the BamHI and XbaI sites in the multi-cloning sequence of the
pcDNA3 vector: 50-CGGGATCCGCCGCCGCCATGGACTACAAGGACG
ATGATGACAAGGGCTCTACTGTTCACGAAATC-30 (sense) and 50-GCT
CTAGATTAGTCATCTCCACCACACAGGTAC-30 (antisense); the FLAG
sequence is underlined.
2.3. Cell culture
The human breast cancer cell line MDA-MB-231-luc-D3H2LN
(Xenogen), the human prostate cancer cell line 22Rv1 (ATCC),
and the human prostate cancer cell line PC3 (ATCC) were cultured
in RPMI 1640 (Invitrogen) containing 10% heat-inactivated fetal
bovine serum and an antibiotic solution at 37 C in 5% CO2. The
human osteosarcoma cell line 143B (ATCC) and the human hepato-
cellular carcinoma cell line Huh-7 (RIKEN BRC) were cultured in
Dulbecco’s modified Eagle’s medium (Invitrogen) containing 10%
heat-inactivated fetal bovine serum and an antibiotic solution at
37 C in 5% CO2.
2.4. Preparation of conditioned medium and EVs
Cells were seeded in 15 cm dish at 3  106 cells (20 mL per
dish). Before collection of the culture medium, the cells were
washed with PBS, and the medium was switched to Advanced
RPMI containing an antibiotic–antimycotic and 2 mM L-glutamine
(without FBS). The conditioned medium was collected after incu-
bation for 48 h. EVs were purified by differential centrifugation
as described previously [8]. To thoroughly remove cellular debris,
the supernatant was filtered with a 0.22-lm filter unit (Millipore).
Then, the CM was ultracentrifuged at 110000g for 70 min at 4 C.The pellets were washed with 11 mL PBS, and after ultracentrifuga-
tion, they were resuspended in PBS. The putative EV fraction was
measured with regard to protein content using a Quant-iTTM Protein
Assay with a Qubit2.0 Fluorometer (Invitrogen). The amount of
EVs obtained is 2 lg from 106 cells in PC3 cells. For proteomic
analysis, we collected EVs from 500 mL (7.5  107 cells) of condi-
tioned medium. For qRT-PCR, we collected EVs from 40 mL
(6  106 cells) of conditioned medium.
2.5. Preparation of EV lysates
Whole EV lysates were prepared using Mammalian Protein
Extract Reagent (Thermo Scientific). Then, whole EV lysates were
transferred to a 1.5 mL tube and treated by sonication.
2.6. Proteomic analysis
For the proteomic analysis, we used EVs purified from 500 mL of
conditioned medium for each cell line. A mass spectrometric anal-
ysis was carried out using LC–MS/MS [13,14]. The LC–MS/MS
parameter and methods were described previously [15]. The data-
base search was performed with MASCOT Deamon (Matrix
Science) [16–18]. The generated pkl files were submitted to
SWISS-PROT (12012_02) and NCBInr (20120303); the search
parameters were as follows: fixed modifications, car-
bamidomethyl; variable modifications, oxidation (M); missed
cleavages, up to 1; monoisotopic peptide tolerance, 1.0 Da; taxon-
omy, human and MS/MS tolerance, 0.5 Da. To automatically elimi-
nate very-low-scoring random peptide matches, the ion score
cutoff was set to 20; thus homologous proteins are more likely to
collapse into a single hit, which avoids the need to choose between
them. MOWSE scores are reported as 10  log10 (P), where P is
the absolute probability; a probability of 10–20 thus became a
score of 200 [19].
2.7. Transient transfection assays
Transfection of a small interfering RNA (siRNA) was accom-
plished using the DharmaFECT transfection reagent (Thermo Scien-
tific) according to the manufacturer’s protocol. AllStars Negative
Control siRNA (Qiagen) was used as a negative control.
2.8. Measurement of size distribution by nanoparticle tracking analysis
Nanoparticle tracking analysis was conducted using the Nano-
Sight LM10-HS system (NanoSight Ltd.) for EVs that were resus-
pended in PBS. We quantified the relative number of released
EVs collected from the distinct culture conditions concomitantly
for each experiment to directly compare the treated and control
samples.
2.9. Cell proliferation assay (MTS assay)
A total of 5000 cells per well were seeded in 96-well plates; the
following day, the cells were transfected with siRNAs. After 3 days
of culture, cell viability was measured using Cell Counting Kit-8
(Dojindo) according to manufacturer’s protocol. The absorbance
was measured at 450 nm using the EnVision system (Wallac).
2.10. Isolation of miRNAs and quantitative real-time PCR (qRT-PCR)
Total RNAs were extracted from cultured cells using QIAzol and
miRNeasy Mini Kit (Qiagen) according to the manufacturer’s proto-
col. PCR was performed in 96-well plates using a 7300 Real-Time
PCR System (Applied Biosystems). TaqMan qRT-PCR kits were
purchased from Applied Biosystems. Reverse transcription (Applied
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2.11. Immunoblot analysis
SDS–PAGE gels were calibrated using Precision Plus protein
standards (161-0375) (Bio-Rad), and anti-ANXA2 (1:200),
anti-CD9 (1:200), anti-CD81 (1:200) and anti-Alix (1:200) were
used as primary antibodies. A peroxidase-labeled anti-mouse sec-
ondary antibody was used at a dilution of 1:1000. The primary-
antibody-recognized protein bands were visualized using a
peroxidase-conjugated secondary antibody and enhanced
chemiluminescence with an ECL Plus Western blotting detection
system (RPN2132; GE HealthCare). Then, Luminescent images
were captured using a LuminoImager (LAS-3000; FujiFilm Inc.).
2.12. Immunoprecipitation–qRT-PCR
Anti-FLAG M2 magnetic beads (20 lL) (Sigma–Aldrich) were
washed 3 times in TBS containing 1 mM Ca2+, resuspended in
1 mL of EV sample, and incubated overnight at 4 C with gentle
mixing. The beads were then washed 3 times in TBS containing
1 mM Ca2+ to remove all of the non-specifically bound proteins.Fig. 1. ANXA2 is involved in the extracellular export of miRNAs. PC3 cells were transfecte
siRNA. (A) After 2 days of culture, cell extracts were subjected to qRT-PCR. The expression
of culture, cell growth was assessed by an MTS assay. The values on the y-axis are relative
cell lysate (upper panels) and the conditioned medium (lower panels) were subjected to q
210 (right panels) were analyzed. All data are shown as the mean ± SD *P < 0.05, **P < 0.01
All experiments were repeated at least 3 times. Statistical analyses were performed usinFor the qRT-PCR analysis, 500 lL of QIAzol (Qiagen) was added,
and the samples were vortexed prior to use.
2.13. Statistical analysis
Data are presented as the mean ± SD, and the experimental
points show the average of at least triplicates. All experiments
were repeated at least 3 times. Statistical analyses were performed
using Student’s t-test.
3. Results
3.1. EV proteins identified by proteomic analysis
To identify the molecules responsible for the common loading
of miRNAs into EVs, we performed a proteomic analysis using
LC–MS/MS (Table S1). For this proteomic analysis, EVs were iso-
lated by ultracentrifugation from 4 human cancer cell lines, includ-
ing breast cancer, prostate cancer, osteosarcoma, and
hepatocellular carcinoma lines. From the proteomic data obtained,
we selected 8 candidates—glyceraldehyde 3-phosphate dehydro-
genase (GAPDH), annexin A1 (ANXA1), ANXA2, annexin A5
(ANXA5), annexin A6 (ANXA6), elongation factor 1-c (EEF1G),d with control, GAPDH, ANXA1, ANXA2, ANXA5, ANXA6, EEF1G, EEF2, and HIST4H4
level of the cells treated with the control siRNA was defined as 1.0. (B) After 3 days
to the cell viability of the control siRNA treatment, which is defined as 100. (C) The
RT-PCR. Expression levels of miR-16 (left panels), miR-21 (middle panels), and miR-
, and ***P < 0.001 and the experimental points show the average of at least triplicates.
g Student’s t-test.
Fig. 2. ANXA2 recruits miRNAs into EVs. EVs were collected from PC3 cells transiently transfected with control, ANXA2, and ANXA5 siRNA. Both cells and EVs were subjected
to miRNA microarray analysis. (A) The clustering analysis of EVs is shown. (B) Number of miRNAs in EVs and cells detected by the microarray analysis. (C) The clustering
analysis of EVs and cells is shown. Yellow to Blue, color-range gradient displaying the expression level. (D) Scatter plots of correlation coefficient analysis were performed.
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commonly present in EVs from at least 2 cancer cell lines (Fig. S1).
3.2. Inhibition of ANXA2 expression decreases the amount of
extracellular miRNAs
To examine whether these 8 candidate proteins can participate
in the loading process of miRNAs into EVs, we investigated both
intracellular and extracellular miRNA levels by qRT-PCR after
knocking down each of these genes. We analyzed the expression
of miR-16, miR-21, and miR-210, as these 3 miRNAs have been
shown to be abundant in EVs [20]. Following transfection with siR-
NAs, we confirmed that each candidate gene was successfully
silenced (Fig. 1A) without any cytotoxic effects (Fig. 1B). Notably,
after the silencing of ANXA1, ANXA2, ANXA5, and EEF1G, the
amount of all the tested miRNAs significantly decreased in the
EVs, though the corresponding intracellular expression levels of
these miRNAs were not changed (Fig. 1C). Among these proteins,
ANXA2 and ANXA5 silencing showed the most significant results.
Consequently, we hypothesized that ANXA2 and ANXA5 could rep-
resent major players in the recruitment of miRNAs into EVs and
decided to focus on these proteins for further investigation.
3.3. ANXA2 participates in non-selective loading of miRNAs into EVs
To reveal whether ANXA2 and ANXA5 globally recruit miRNAs
without sequence selectivity, we performed a microarray analysis
on EVs derived from ANXA2-knockdown, ANXA5-knockdown,
and control cells and found that ANXA5 silencing affected EV
miRNA profile patterns more significantly than ANXA2 silencing
(Fig. 2A). These results demonstrated that ANXA2 participates in
the loading of miRNAs into EVs in a relatively non-selective way.
Thus, we focused on ANXA2 for further investigation and analyzed
microarray data for EVs derived from ANXA2-knockdown and con-
trol cells, since as noted in the Introduction, our primary goal is toexploration for proteins that commonly recruit miRNAs into EVs
(Table S2). This analysis revealed that 214 miRNAs could be found
in both cells and EVs after ANXA2 siRNA transfection (Fig. 2B and
Table S2). Interestingly, it appeared that ANXA2 silencing did not
affect the miRNA profiles observed in cells and EVs (Fig. 2C). Next,
a cellular miRNA comparison between ANXA2 silencing and the
control showed a high degree of concordance (R2 = 0.99)
(Fig. 2D). In addition, the comparison between ANXA2 silencing
and the control in EVs showed good concordance (R2 = 0.69)
(Fig. 2D).
3.4. Characterization of ANXA2 in EVs
To confirm that ANXA2 is present in EVs, we analyzed the
amount of ANXA2 in EVs using western blotting. As shown in
Fig. 3A, the ANXA2 protein was evident in both EVs and cells. In
addition, the levels of ANXA2 in EVs dramatically decreased after
ANXA2 silencing (Fig. 3B), indicating that the abundance of ANXA2
in EVs is correlated to the expression level of ANXA2 in cells. To
eliminate the possibility that ANXA2 silencing could decrease the
number of secreted EVs, the particle number and size of EVs were
measured by nanoparticle tracking analysis. The number of EVs
derived from PC3 cells after ANXA2 silencingwas not changed com-
pared to control siRNA-treated cells (Fig. 3C), with the size of EVs
derived from PC3 cells showing a peak between 100 and 150 nm,
regardless of the level of ANXA2 (Fig. 3D). This finding indicates that
ANXA2 did not affect the EV biogenesis and secretion process. To
explore the relationship between ANXA2 and EV miRNA abun-
dance, we isolated EVs from 2 prostate cancer cell lines expressing
high (PC3) or low (22Rv1) levels of ANXA2 (Fig. 3E). A positive cor-
relation between ANXA2 and miRNA levels in EVs was observed,
whereas the intracellular expression levels of these miRNAs did
not show any correlation with ANXA2 between the PC3 and
22Rv1 cells (Fig. 3F). These results strongly suggest that ANXA2
may participate in the loading process of miRNAs into EVs.
K. Hagiwara et al. / FEBS Letters 589 (2015) 4071–4078 40753.5. ANXA2 recruits a set of miRNAs into EVs
To clarify whether ANXA2 can regulate the recruitment of miR-
NAs into EVs, we examined a specific set of miRNAs, including miR-
16, miR-21, miR-24, miR-29a, miR-100, miR-125, let-7a, and let-
7b, as our previous study indicated the abundance of these miRNAs
in PC3 cell-derived EVs [20]. All of the tested miRNAs in the EVs
derived from ANXA2-silenced cells were found to be downregu-
lated (Fig. 4A). Next, the amount of EV miRNA was analyzed in
ANXA2-overexpressing cells. Following transfection with an
ANXA2 overexpressing vector, increased levels of ANXA2 in both
the cells and EVs were confirmed by qRT-PCR and western blotting
(Fig. 4B and C). The results showed that ANXA2 overexpression
increased the level of miR-16 in EVs without affecting the cellular
level of miR-16 (Fig. 4D). These results reinforced our evidence that
ANXA2 regulates the packaging process of miRNAs into EVs.
3.6. ANXA2 is associated with miRNAs in EVs
To examine the binding ability of ANXA2 with miRNAs, we
designed a FLAG-ANXA2 overexpression vector for immunoprecip-
itation (Fig. 5A). After expression of FLAG-ANXA2 in HEK293 cells,Fig. 3. ANXA2 is identified in EVs. (A) Whole-cell lysates and EVs were collected from P
(500 ng), lane 2: EV (500 ng), lane 3: recombinant ANXA2 (10 ng), lane 4: recombinant A
(0.01 ng). EVs were collected from PC3 cells transiently transfected with control or ANXA2
CD81, or Alix. (C) Nanoparticle concentrations per mL of EVs. (D) Size distribution of EVs
profile of the average size for each sample (n = 3). (E) ANXA2 expression was examined b
(right panels) were collected from PC3 cells and 22Rv1 cells. Expression levels of miR-16
using qRT-PCR. All data are shown as the mean ± SD *P < 0.05, **P < 0.01, and ***P < 0.001 a
were repeated at least 3 times. Statistical analyses were performed using Student’s t-teANXA2 was immunoprecipitated from the EV lysate using an anti-
FLAG antibody (Fig. 5B), revealing that the ANXA2 fraction con-
tained a higher amount of miRNAs in the presence of Ca2+ at
1 mM (Fig. 5C). These findings collectively indicated that ANXA2
could specifically bind miRNAs in EVs in a calcium-dependent
manner.
4. Discussion
Although a number of reports have suggested that miRNAs in
EVs have the potential to be used in RNAi-based therapy and for
diagnosis of various diseases, the loading process of miRNAs into
EVs remains unclear. In this study, we demonstrated that ANXA2
plays a major role in the loading of miRNAs into EVs.
As noted in the Introduction section, the goal of this study was
to search for proteins that commonly recruit miRNAs into EVs, and
we identified ANXA2 as such a protein. The EV database ExoCarta
(http://exocarta.org) provides evidence that over 4000 proteins
can be contained within EVs, including a calcium channel-
associated protein, CACNA2D4, and an mRNA-binding protein,
SERBP1 [21]. However, we cannot rule out the possibility that
other proteins might contribute to miRNA loading into EVs. Indeed,C3 cells. ANXA2 expression was analyzed using immunoblotting. Lane 1: cell lysate
NXA2 (1 ng), lane 5: recombinant ANXA2 (0.1 ng), and lane 6: recombinant ANXA2
siRNA. (B) A 500 ng sample of EV protein was used for the detection of ANXA2 CD9,
determined by the NanoSight system. Data represent the average size distribution
y qRT-PCR in PC3 cells and 22Rv1 cells. (F) Whole-cell lysates (left panels) and EVs
(upper panels), miR-21 (middle panels), and miR-210 (lower panels) were analyzed
nd the experimental points show the average of at least triplicates. All experiments
st.
Fig. 5. ANXA2 is associated with miRNAs in EVs. (A) Schematic representation of the FLAG-tagged ANXA2-overexpressing vector. The coding sequence of ANXA2 was inserted
into pcDNA3 and fused with the FLAG tag at the N-terminus. SV40A indicates an SV40 polyadenylation signal. HEK293 cells were transiently transfected with the control or
FLAG-tagged ANXA2-overexpressing vector. (B) ANXA2 was immunoprecipitated from EV lysate and immunoblotted using an anti-ANXA2 antibody. (C) Expression levels of
miR-16 (left panels), miR-21 (middle panels), and miR-210 (right panels) in ANXA2 immunoprecipitates from EV lysates with Ca2+ were analyzed. All data are shown as the
mean ± SD *P < 0.05, **P < 0.01, and ***P < 0.001 and the experimental points show the average of at least triplicates. All experiments were repeated at least 3 times. Statistical
analyses were performed using Student’s t-test.
Fig. 4. ANXA2 contributes to the process of miRNA loading into EVs. (A) EVs were collected from PC3 cells transiently transfected with control or ANXA2 siRNA and subjected
to miRNA qRT-PCR. (B) HEK cells were transiently transfected with a control or ANXA2-overexpressing vector. After 2 days of culture, cell and EV extracts were subjected to
qRT-PCR. (C) A 100 ng sample of EV proteins was used for the detection of ANXA2 (upper panel) or CD9 (lower panel). (D) Expression levels of miR-16 were analyzed in cells
and EVs. All data are shown as the mean ± SD *P < 0.05, **P < 0.01, and ***P < 0.001 and the experimental points show the average of at least triplicates. All experiments were
repeated at least 3 times. Statistical analyses were performed using Student’s t-test.
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specific miRNAs into EVs [22]. In addition, we found that the
knockdown of ANXA1, ANXA5, and EEF1G could also decrease
the abundance of miRNAs in culture supernatant (Fig. 1C). Further-
more, we confirmed by qRT-PCR that ANXA5 silencing decreased
the amount of miR-16 and miR-21 in EVs (data not shown).
Although ANXA2 regulated the loading of miRNAs into EVs in a
sequence independent manner, our miRNA microarray analysis
showed that ANXA2 silencing decreased the relative abundance
of only 6 miRNAs (Fig. S2). These observations suggest that ANXA2
might have a selective affinity for a small number of specific miR-
NAs during their packaging into EVs. Notably, we demonstrated
that ANXA5 silencing more significantly affected EV miRNA pro-
files compared to ANXA2 silencing (Fig. 2A). These observations
reinforce our thesis that the role of ANXA2 in the loading process
of miRNAs into EVs is largely non-selective.
Interestingly, we found that the ANXA2-associated enrichment
of miRNAs in EVs was Ca2+ dependent. Accordingly, some reports
have supported evidence that EVs contain a high concentration
of Ca2+. For instance, secretory granules contain high amounts of
Ca2+ ions in endocrine cells [23]. Emmanouilidou et al. also
reported that an increase in the intracellular Ca2+ concentration
can stimulate EV secretion [24]. Moreover, monensin, which
activates Ca2+ entry by reversing the activity of the Na+/Ca2+
exchanger, induces the accumulation of Ca2+ in the enlarged
multivesicular bodies, from which EVs are derived [25]. Thus, our
results now propose a hypothesis that the enrichment of Ca2+ in
EVs could promote in the loading process of miRNA mediated by
ANXA2.
We found that ANXA2 binds miRNAs in EVs (Fig. 5C). However,
we cannot exclude the possibility that ANXA2 interacts indirectly
with miRNAs. Indeed, it has been reported that ANXA2 has the
ability to be associated with several proteins such as p11 and tPA
[26,27]. Moreover, ANXA2 can bind directly to both mRNA and
ribonucleotide homopolymers [28,29]. Thus, there is a possibility
that ANXA2 recruits miRNAs via its interaction with other
miRNA-associated proteins. We are planning to investigate this
possibility in our future studies.
The discovery of EVs as carriers of miRNAs led to the proposal
that EVs could be used as exogenous miRNA delivery systems for
gene therapy [30]. Indeed, our group previously reported that
EVs from normal epithelial prostate cells inhibit the proliferation
of prostate cancer cells in vitro; in this study, the tumor-
suppressive miRNA miR-143 was able to inhibit cell growth
through the downregulation of KRAS and ERK5 expression after
its transfer into recipient cells [20]. The main limitation of EV-
based therapeutic strategies is the requirement of large amounts
of EVs. Therefore, the development of effective methods for signif-
icantly increasing the amount of miRNAs in EVs remains a major
challenge. In the present study, we found that ANXA2 overexpres-
sion increased the amount of EV miRNAs (Fig. 4D). Thus,
overexpressing ANXA2 could represent a promising strategy to sig-
nificantly increase the amount of miRNAs packaged into EVs.
Our findings indicate that ANXA2 plays a crucial role in the
loading process of miRNAs into EVs. To the best of our knowledge,
our results present the first evidence of a molecular process
underlying miRNA loading into EVs in a sequence independent
manner. However, further studies will be still required for the
entire understanding of the mechanisms governing the miRNA
loading into EVs. For example, it is not clear whether ANXA2 binds
directly to miRNAs, or requires any other mediating molecules
such as Ago2. Although Ago2 is one of the most important
miRNA-binding proteins, a previous study reported that EVs do
not contain Ago2 [31]. Instead, it is suggested that Ago2 complexes
carry a population of circulating microRNAs that are not associated
with EVs in human plasma [32]. Thus, further investigation will berequired to clarify (1) whether ANXA2 can bind directly to its tar-
get miRNAs, and if it is not the case, (2) what molecule mediates
the ability of ANXA2 to form complexes with miRNAs.
In conclusion, our study provides evidence for an ANXA2-
dependent loading mechanism of miRNA into EVs. To our knowl-
edge, this is the first report that highlights such a specific protein
in the recruitment of miRNAs into EVs. Importantly, we reveal that
ANXA2 regulates the loading of miRNA into EVs in a sequence
independent manner. As ANXA2 overexpression significantly
increased the amount of EV miRNAs, we anticipate that modulat-
ing ANXA2may represent an interesting strategy to enrich EV miR-
NAs for future biomedical applications.
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